338 filings
8-K
AGRX
Agile Therapeutics Inc
21 May 24
Entry into a Material Definitive Agreement
8:30am
10-Q
2024 Q1
AGRX
Agile Therapeutics Inc
Quarterly report
15 May 24
4:30pm
8-K
AGRX
Agile Therapeutics Inc
15 May 24
Agile Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
4:15pm
10-K/A
2023 FY
AGRX
Agile Therapeutics Inc
Annual report (amended)
29 Apr 24
4:30pm
8-K
AGRX
Agile Therapeutics Inc
9 Apr 24
Results of Operations and Financial Condition
8:30am
8-K
s8w14 tjd6
28 Mar 24
Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update
9:06am
8-K
9xdm4m6srnwj7rohdic2
25 Mar 24
Agile Therapeutics Announces Delisting from Nasdaq
4:30pm
8-K
gr0v11iq 3hi8hmoje
14 Mar 24
Agile Therapeutics Completes Pay-off of Debt and Remains Focused on Business Plan Execution
4:45pm
424B5
azh7xr8dx0t2kuoj
23 Feb 24
Prospectus supplement for primary offering
4:57pm
424B5
wzmduwxkjraf6m
23 Feb 24
Prospectus supplement for primary offering
4:55pm
8-K
93ersi7s98wyx8lkjd2
23 Feb 24
Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds
4:30pm
8-K
8uocyy
15 Feb 24
Net Revenue for Full Year 2023 Expected to be in the Range of $20 to $21 Million, an Increase of 84% to 93% Compared to Full Year 2022
4:45pm
8-K
zioxol hqz4rs43
6 Dec 23
Other Events
8:00am
8-K
tz34iog
4 Dec 23
Entry into a Material Definitive Agreement
8:00am